X4 Pharmaceuticals, Inc. (XFOR)

NASDAQ: XFOR · IEX Real-Time Price · USD

1.130

-0.160 (-12.40%)

At close: Apr 25, 2024, 4:00 PM

1.170

+0.040 (3.54%)

After-hours: Apr 25, 2024, 7:57 PM EDT

X4 Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015
Revenue	0	0	0	3	0	0	0	0	0
Gross Profit	0	0	0	3	0	0	0	0	0
Selling, General & Admin	35.51	27.02	24.7	20.94	17.64	8.74	5.18	6.52	2.12
Research & Development	72.02	61.06	50.65	41.93	30.16	20.35	17.07	17.83	12.71
Other Operating Expenses	0	-0.51	9.76	0	3.9	0	0	0	0
Operating Expenses	107.52	87.57	85.11	62.87	51.7	29.09	22.25	24.35	14.83
Operating Income	-107.52	-87.57	-85.11	-59.87	-51.7	-29.09	-22.25	-24.35	-14.83
Interest Expense / Income	5.78	3.99	3.64	2.69	2.15	0.72	0.49	2.52	0.47
Other Expense / Income	-12.21	2.28	-0.07	-0.58	-1.04	3.48	-0.74	-3.89	-2.08
Pretax Income	-101.09	-93.84	-88.68	-61.98	-52.81	-33.29	-21.99	-22.98	-13.22
Income Tax	0.08	0.03	0.02	0.15	0	0	0	0	0
Net Income	-101.17	-93.87	-88.7	-62.13	-52.81	-33.29	-21.99	-22.98	-13.22
Preferred Dividends	0	2.55	13.94	0	0.59	3.02	3	0.03	0.02
Net Income Common	-101.17	-96.41	-102.64	-62.13	-53.4	-36.31	-24.99	-23	-13.24
Shares Outstanding (Basic)	178	64	26	20	12	0	0	0	0
Shares Outstanding (Diluted)	178	64	26	20	12	0	0	0	0
Shares Change	179.91%	146.71%	28.25%	74.13%	2411.98%	0.22%	435.12%	0.96%	-
EPS (Basic)	-0.57	-1.52	-3.99	-3.09	-4.63	-79.15	-54.58	-268.74	-156.12
EPS (Diluted)	-0.57	-1.52	-3.99	-3.09	-4.63	-79.15	-54.58	-268.74	-156.12
Free Cash Flow	-96.57	-77.21	-71.52	-60.18	-48.23	-25.42	-21.69	-21.71	-10.99
Free Cash Flow Per Share	-0.54	-1.22	-2.78	-3.00	-4.18	-55.38	-47.36	-253.68	-129.59
Gross Margin	-	-	-	100.00%	-	-	-	-	-
Operating Margin	-	-	-	-1995.80%	-	-	-	-	-
Profit Margin	-	-	-	-2071.03%	-	-	-	-	-
Free Cash Flow Margin	-	-	-	-2006.00%	-	-	-	-	-
EBITDA	-93.32	-87.85	-83.15	-58.07	-49.99	-32.46	-21.43	-20.18	-12.36
EBITDA Margin	-	-	-	-1935.50%	-	-	-	-	-
Depreciation & Amortization	2	1.99	1.89	1.23	0.67	0.1	0.07	0.29	0.39
EBIT	-95.31	-89.85	-85.04	-59.3	-50.66	-32.57	-21.5	-20.46	-12.75
EBIT Margin	-	-	-	-1976.50%	-	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).